The effect of ascertainment bias in evaluating gestational antidepressant exposure

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 18, Issue 1, 2011, Pages

  Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

AMNIOCENTESIS; ANXIETY DISORDER; ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DEPRESSION; DRUG SCREENING; ECHOCARDIOGRAPHY; EMERGENCY WARD; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HEALTH CARE UTILIZATION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; PRENATAL DRUG EXPOSURE; SYSTEMATIC ERROR;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; PAROXETINE; PREGNANCY;

EID: 79959812466     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14: 823-827.
2. Berard A, Ramos E, Oraichi D, et al. Gestational exposure to paroxetine and cardiac malformations in infants: a nested case-control study. Birth Defects Res A Clin Mol Teratol 2006; 76: 335.
3. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac defects: a meta-analysis of epidemiological studies. Birth Defects Res A ClinMol Teratoil 2010; 88: 159-70.
4. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749-52.
5. Minkovitz CS, Strobino D, Scharfstein D, et al. Maternal depressive symptoms and children's receipt of health care in the first 3 years of life. Pediatrics 2005; 115: 306-314.
6. Williams PR, Argent EH, Chalmers C. A study of an urban health centre: factors influencing contact with mothers and their babies. Child Care Health Dev 1981; 7: 255-266.
7. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
8. Levy AR, Mayo NE, Grimard G. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995; 142: 428-436.
9. Lacasse AM, Rey E, Ferreira E, et al. Nausea and vomiting of pregnancy: are there multiethnic differences in the reporting and management? Pharmacoepidemiol Drug Saf 2005; 14: S203.
10. Roy E, Haley N, Leclerc P, et al. Mortality in a cohort of street youth in Montreal. JAMA 2004; 292: 569-574.
11. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G. Paroxetine and congenital malformations: metaanalysis and consideration of potential confounding factors. Clin Ther 2007; 29: 918-26.
12. Einarson A. Influence of the media on women taking antidepressants during pregnancy. J Clin Psychiatry 2009; 70: 1313-4.
13. Roguin N, Du ZD, Barak M, Nasser N, Hershkowitz S, Milgram E. High prevalence of muscular ventricular septal defects in neonates. JACC 1995; 26: 1545-8.
14. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. [published correction appears in JAMA. 2006; 296: 170]. JAMA 2006; 295: 499-507.